Company intelligence / Profile preview

ImmunoFlex Therapeutics

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Phase 1

Overview

ImmunoFlex has developed pharmaceutical-grade health products aimed at enhancing immune preparedness and resilience, with a focus on preventing and reducing the severity of viral infections. As of mid-2021, they completed a clinical study and filed US/international patents but have not published detailed results or advanced to late-stage trials.

Therapeutic areas: Infectious Diseases
Modalities: Pharmaceutical-grade health productsCannabinoid-linked compounds
Industry: Biotech

Drug pipeline

1 asset

CBD + THC + NAC combination

Phase 1

Indications: COVID-19 long-haul, Viral diseases, Immune system disorders

Beyond the preview

Go deeper on ImmunoFlex Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoFlex Therapeutics.

Explore the full profile